Grace Therapeutics (GRCE) Retained Earnings (2017 - 2026)
Grace Therapeutics (GRCE) posted Retained Earnings of -$6.0 million for Q1 2026, little changed sequentially from -$6.0 million in Q4 2025, and down 102.06% YoY from $293.3 million in Q1 2025.
Grace Therapeutics (GRCE) Retained Earnings (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Retained Earnings for 10 years, with the latest figure at -$6.0 million in Q1 2026.
- Quarterly Retained Earnings fell 102.06% year-over-year to -$6.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (down 102.06% YoY) and the FY2026 annual result came in at -$6.0 million, down 102.06% from the prior year.
- Retained Earnings steadied at -$6.0 million in Q1 2026 per GRCE's latest filing, from -$6.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at $293.8 million in Q3 2025 and troughed at -$208.0 million in Q4 2023.
- A 5-year average of $62.6 million and a median of -$6.0 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings sank 147.85% in 2023, then jumped 4963.13% in 2025.
- Over 5 years, Retained Earnings stood at -$169.2 million in 2022, then declined by 22.92% to -$208.0 million in 2023, then surged by 234.4% to $279.5 million in 2024, then sank by 102.16% to -$6.0 million in 2025, then changed by 0.0% to -$6.0 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$6.0 million, -$6.0 million, and $293.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 4.38 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 298.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298.52 Mn |
| Mar 31, 2026 | -6.04 Mn |
| Dec 31, 2025 | -6.04 Mn |
| Sep 30, 2025 | 293.84 Mn |
| Jun 30, 2025 | 293.64 Mn |
| Mar 31, 2025 | 293.33 Mn |
| Dec 31, 2024 | 279.50 Mn |
| Sep 30, 2024 | 18.30 Mn |
| Jun 30, 2024 | -6.04 Mn |
| Mar 31, 2024 | 278.90 Mn |
| Dec 31, 2023 | -207.95 Mn |
| Sep 30, 2023 | -6.04 Mn |
| Jun 30, 2023 | -6.04 Mn |
| Mar 31, 2023 | -6.04 Mn |
| Dec 31, 2022 | -169.18 Mn |
| Sep 30, 2022 | 13.20 Mn |
| Jun 30, 2022 | 12.62 Mn |
| Mar 31, 2022 | -6.04 Mn |
| Dec 31, 2021 | -151.93 Mn |
| Sep 30, 2021 | -148.16 Mn |